<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003893</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067062</org_study_id>
    <secondary_id>CRC-TU-BR3015</secondary_id>
    <secondary_id>EU-99005</secondary_id>
    <nct_id>NCT00003893</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer</brief_title>
  <official_title>Sequencing of Chemotherapy and Radiotherapy in Adjuvant Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage&#xD;
      tumors cells. Combining chemotherapy with radiation therapy may kill more tumor cells. It is&#xD;
      not yet known which regimen of chemotherapy plus radiation therapy is more effective for&#xD;
      early-stage breast cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of&#xD;
      adjuvant chemotherapy plus radiation therapy in treating women who have early-stage breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the effects of synchronous vs sequential adjuvant chemotherapy and radiotherapy&#xD;
           on local recurrence, disease-free and overall survival, and treatment delay in women&#xD;
           with early-stage breast cancer.&#xD;
&#xD;
        -  Compare the safety of these regimens, in terms of dose intensity and toxicity, in this&#xD;
           patient population.&#xD;
&#xD;
        -  Compare the quality of life and cosmetic outcome in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      clinical oncologist, axillary clearance (yes vs no), radiotherapy boost intent (boost vs no&#xD;
      boost), and chemotherapy intent (cyclophosphamide, methotrexate, and fluorouracil [5-FU] vs&#xD;
      anthracycline-containing regimen). Patients are randomized to one of two treatment arms.&#xD;
&#xD;
      Patients receive any chemotherapy regimen that includes cyclophosphamide, methotrexate, and&#xD;
      5-FU. Some regimens may also include epirubicin, doxorubicin, mitoxantrone, and/or mitomycin.&#xD;
      Chemotherapy repeats every 3 weeks for 4-8 courses.&#xD;
&#xD;
        -  Arm I (synchronous chemoradiotherapy): Patients receiving synchronous therapy receive&#xD;
           any of the above chemotherapy regimens plus daily radiotherapy between courses 2 and 3&#xD;
           OR courses 5 and 6 of chemotherapy. Radiotherapy is administered for 3-5 weeks.&#xD;
&#xD;
        -  Arm II (sequential chemoradiotherapy): Patients receiving sequential therapy receive any&#xD;
           of the above chemotherapy regimens followed by daily radiotherapy beginning after&#xD;
           completion of all chemotherapy (after course 6 or 8). Radiotherapy is administered for&#xD;
           3-5 weeks.&#xD;
&#xD;
      Treatment in both arms continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Quality of life is assessed before chemotherapy, 2-3 weeks after the completion of all&#xD;
      treatment, and then at 1, 2, and 5 years.&#xD;
&#xD;
      Patients are followed annually for 10 years.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 2,250 patients (1,125 per treatment arm) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">2250</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CMF regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer&#xD;
&#xD;
               -  Early-stage disease&#xD;
&#xD;
                    -  No metastatic disease&#xD;
&#xD;
               -  Complete surgical excision of tumor&#xD;
&#xD;
          -  Planned use of adjuvant chemotherapy and radiotherapy&#xD;
&#xD;
          -  If participating in the cosmetic outcome evaluation portion of the study, must have&#xD;
             unilateral disease&#xD;
&#xD;
          -  Hormone receptor status&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Bone marrow function adequate&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Hepatic function adequate&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Renal function adequate&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Cardiac function adequate&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior malignancy except basal cell or squamous cell skin cancer or carcinoma&#xD;
             in situ&#xD;
&#xD;
          -  No other medical or social condition that would preclude study compliance&#xD;
&#xD;
          -  Fit to receive both adjuvant chemotherapy and radiotherapy (administered either&#xD;
             synchronously or sequentially)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No concurrent epirubicin and doxorubicin as a study combination chemotherapy regimen&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior or concurrent hormonal therapy allowed&#xD;
&#xD;
          -  No concurrent tamoxifen if treated with methotrexate, mitomycin, and mitoxantrone as a&#xD;
             study combination chemotherapy regimen&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent internal mammary chain irradiation&#xD;
&#xD;
          -  No concurrent orthovoltage irradiation to the whole breast&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Concurrent participation in another clinical trial allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Indy Fernando, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Bowden SJ, Fernando IN, Burton A. Delaying radiotherapy for the delivery of adjuvant chemotherapy in the combined modality treatment of early breast cancer: is it disadvantageous and could combined treatment be the answer? Clin Oncol (R Coll Radiol). 2006 Apr;18(3):247-56. doi: 10.1016/j.clon.2005.11.010.</citation>
    <PMID>16605056</PMID>
  </reference>
  <reference>
    <citation>Fernando I, Bowden S, Dunn J: The combination of chemotherapy and radiotherapy in the adjuvant treatment of breast cancer. [Abstract] Radiother Oncol 58 (Suppl 1): A-34, S10, 2001.</citation>
  </reference>
  <reference>
    <citation>Fernando IN. The role of radiotherapy in patients undergoing mastectomy for carcinoma of the breast. Clin Oncol (R Coll Radiol). 2000;12(3):158-65. doi: 10.1053/clon.2000.9143.</citation>
    <PMID>10942332</PMID>
  </reference>
  <verification_date>November 2001</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage I breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

